Literature DB >> 15723969

Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus.

Damiano Rizzoni1, Enzo Porteri, Carolina De Ciuceis, Intissar Sleiman, Luigi Rodella, Rita Rezzani, Silvia Paiardi, Rossella Bianchi, Giuseppina Ruggeri, Gianluca E M Boari, Maria Lorenza Muiesan, Massimo Salvetti, Francesca Zani, Marco Miclini, Enrico Agabiti Rosei.   

Abstract

Structural alterations of subcutaneous small resistance arteries are associated with a worse clinical prognosis in hypertension and noninsulin-dependent diabetes mellitus (NIDDM). However, no data are presently available about the effects of antihypertensive therapy on vascular structure in hypertensive patients with NIDDM. Therefore, we have investigated the effect of an angiotensin-converting enzyme inhibitor, enalapril, and a highly selective angiotensin receptor blocker, candesartan cilexetil, on indices of subcutaneous small resistance artery structure in 15 patients with mild hypertension and NIDDM. Eight patients were treated with candesartan (8 to 16 mg per day) and 7 with enalapril (10 to 20 mg per day) for 1 year. Each patient underwent a biopsy of the subcutaneous fat from the gluteal region at baseline and after 1 year of treatment. Small arteries were dissected and mounted on a micromyograph and the media-to-internal lumen ratio was evaluated; moreover, endothelium-dependent vasodilation to acetylcholine was assessed. A similar blood pressure-lowering effect and a similar reduction of the media-to-lumen ratio of small arteries was observed with the 2 drugs. Vascular collagen content was reduced and metalloproteinase-9 was increased by candesartan, but not by enalapril. Changes of circulating indices of collagen turnover and circulating matrix metalloproteinase paralleled those of vascular collagen. The 2 drugs equally improved endothelial function. In conclusion, antihypertensive treatment with drugs that inhibit the renin-angiotensin-aldosterone system activity is able to correct, at least in part, alterations in small resistance artery structure in hypertensive patients with NIDDM. Candesartan may be more effective than enalapril in reducing collagen content in the vasculature.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15723969     DOI: 10.1161/01.HYP.0000153308.91043.97

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  22 in total

Review 1.  Inhibition of the renin angiotensin system: implications for the endothelium.

Authors:  Carmine Savoia; Ernesto L Schiffrin
Journal:  Curr Diab Rep       Date:  2006-08       Impact factor: 4.810

Review 2.  Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease.

Authors:  G F M Strippoli; C Bonifati; M Craig; S D Navaneethan; J C Craig
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

3.  Effects of antihypertensive treatment on endothelial function.

Authors:  Agostino Virdis; Lorenzo Ghiadoni; Stefano Taddei
Journal:  Curr Hypertens Rep       Date:  2011-08       Impact factor: 5.369

Review 4.  Fixed-dose combination lercanidipine/enalapril.

Authors:  Philip I Hair; Lesley J Scott; Caroline M Perry
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 5.  Vascular compliance in hypertension: therapeutic implications.

Authors:  Ho Won Lee; Jocelyn Karam; Babar Hussain; Nathaniel Winer
Journal:  Curr Diab Rep       Date:  2008-06       Impact factor: 4.810

Review 6.  Interactions between macro- and micro-circulation: are they relevant?

Authors:  Damiano Rizzoni; Carolina De Ciuceis; Massimo Salvetti; Anna Paini; Claudia Rossini; Claudia Agabiti-Rosei; Maria Lorenza Muiesan
Journal:  High Blood Press Cardiovasc Prev       Date:  2015-04-14

Review 7.  Antihypertensive therapy in diabetes: the legacy effect and RAAS blockade.

Authors:  Massimo Volpe; Francesco Cosentino; Giuliano Tocci; Francesca Palano; Francesco Paneni
Journal:  Curr Hypertens Rep       Date:  2011-08       Impact factor: 5.369

8.  The Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A Randomized, Controlled Trial.

Authors:  Valeria Saglimbene; Suetonia C Palmer; Marinella Ruospo; Patrizia Natale; Ausilia Maione; Antonio Nicolucci; Mariacristina Vecchio; Gianni Tognoni; Jonathan C Craig; Fabio Pellegrini; Giuseppe Lucisano; Jörgen Hegbrant; Rosario Ariano; Olga Lamacchia; Antonio Sasso; Susanna Morano; Tiziana Filardi; Salvatore De Cosmo; Giuseppe Pugliese; Deni A Procaccini; Loreto Gesualdo; Giuseppe Palasciano; David W Johnson; Marcello Tonelli; Giovanni F M Strippoli
Journal:  J Am Soc Nephrol       Date:  2018-11-12       Impact factor: 10.121

Review 9.  Vascular Smooth Muscle Remodeling in Conductive and Resistance Arteries in Hypertension.

Authors:  Isola A M Brown; Lukas Diederich; Miranda E Good; Leon J DeLalio; Sara A Murphy; Miriam M Cortese-Krott; Jennifer L Hall; Thu H Le; Brant E Isakson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-09       Impact factor: 8.311

10.  Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy.

Authors:  Minoru Satoh; Sohachi Fujimoto; Sayaka Arakawa; Toyotaka Yada; Tamehachi Namikoshi; Yoshisuke Haruna; Hideyuki Horike; Tamaki Sasaki; Naoki Kashihara
Journal:  Nephrol Dial Transplant       Date:  2008-07-02       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.